Security
Pharvaris N.V. Ordinary Shares · PHVS
PHVSNASDAQCommon stockCurrentCIK 1830487Updated Oct 4, 2026
Name history
Pharvaris, B.V. · through Feb 4, 2021
PHVS price & chart
Loading TradingView…
NASDAQ:PHVS on TradingView ↗In the news
No coverage from other publishers is available.
Seeking Alpha
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity ↗
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema - Slideshow ↗
SEC disclosures
Pharvaris N.V. files prospectus supplement (424B5) ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · EURSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossEUR | -175,699,397Source | -134,221,527Source | -100,875,068Source | -76,332,557Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodEUR | -1,052,878Source | 98,564Source | -2,819,253Source | — |
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableEUR | -331,339Source | -34,316Source | -41,051Source | 317,612Source |
| AdjustmentsForFinanceCostsEUR | — | — | — | 39,254Source |
| AdjustmentsForIncomeTaxExpenseEUR | -2,168,735Source | -2,767,247Source | -1,108,410Source | -182,824Source |
| AdjustmentsForSharebasedPaymentsEUR | 19,050,394Source | 16,208,533Source | 10,663,226Source | 11,349,200Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsEUR | 11,742,407Source | -7,329,038Source | 2,794,435Source | -11,100,392Source |
| GeneralAndAdministrativeExpenseEUR | 45,344,598Source | 47,124,638Source | 31,338,590Source | 29,339,034Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | 219,013Source | 159,657Source | 220,507Source | 119,527Source |
| ProceedsFromIssuingSharesEUR | — | — | — | 9,609,865Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.26Source | 0.26Source | 0.26Source | 0.26Source |
| AverageEffectiveTaxRatenumber | -0.01Source | -0.01Source | -0.01Source | -0.01Source |
| BasicEarningsLossPerShareEUR/shares | -2.97Source | -2.48Source | -2.63Source | — |
| CurrentTaxExpenseIncomeEUR | 1,087,278Source | 1,033,115Source | 473,623Source | 757,413Source |
| DepreciationRightofuseAssetsEUR | 229,203Source | 174,799Source | 197,770Source | 114,020Source |
| DilutedEarningsLossPerShareEUR/shares | -2.97Source | -2.48Source | -2.63Source | — |
| EmployeeBenefitsExpenseEUR | 58,894,977Source | 46,650,892Source | 32,446,666Source | 26,819,346Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | 11,200,000Source | 10,500,000Source | 6,200,000Source | 7,590,041Source |
| GeneralAndAdministrativeExpenseEUR | 45,344,598Source | 47,124,638Source | 31,338,590Source | 29,339,034Source |
| IncomeTaxExpenseContinuingOperationsEUR | 1,987,901Source | 1,825,024Source | 1,048,805Source | 679,087Source |
| InterestExpenseEUR | — | — | — | 16,105Source |
| InterestExpenseOnLeaseLiabilitiesEUR | 428,846Source | 500,161Source | 15,803Source | 41,633Source |
| OtherEmployeeExpenseEUR | 630,805Source | — | — | — |
| OtherFinanceCostEUR | 172,861Source | 46,914Source | 20,475Source | 23,149Source |
| ProfessionalFeesExpenseEUR | 8,616,327Source | 7,757,750Source | 4,689,462Source | 3,972,771Source |
| ProfitLossBeforeTaxEUR | -173,711,496Source | -132,396,503Source | -99,826,263Source | -75,653,470Source |
| ProfitLossFromOperatingActivitiesEUR | -173,711,496Source | -132,396,503Source | -99,826,263Source | -75,653,470Source |
| ResearchAndDevelopmentExpenseEUR | 124,478,334Source | 98,563,529Source | 65,575,030Source | 57,375,574Source |
Filing attachments
phvs-ex99_1.htm · 6-K · 2026-09-08
September 8, 2026 CHAPTER-3 Topline Data This presentation includes data for an investigational product not yet approved by regulatory authorities. Exhibit 99.1 Disclaimer This Presentation contains certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, without …
Read attachment ↗phvs-ex99_1.htm · 6-K · 2026-09-08
Exhibit 99.1 Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks • Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE • 87% attack rate reduction versus placebo observed in people with HAE Type 1 or Type 2 • All secondary efficacy endpoints met with statistical significance • Well-tolerated safety profile of deucrictibant XR d…
Read attachment ↗phvs-ex99_1.htm · 6-K · 2026-08-12
Exhibit 99.1 Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update • Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 • Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027; MAA validated by the EMA in July 2026 • Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks • Strong financ…
Read attachment ↗phvs-ex99_2.htm · 6-K · 2026-08-12
Exhibit 99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited condensed consolidated interim financial statements, including the notes thereto, for the three and six months ended June 30, 2026 and 2025 included as Exhibit 99.3 to the Repo…
Read attachment ↗phvs-ex99_1.htm · 6-K · 2026-06-11
Exhibit 99.1 Pharvaris Announces Annual General Meeting of Shareholders Zug, Switzerland, June 11, 2026 - Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, J…
Read attachment ↗phvs-ex99_2.htm · 6-K · 2026-06-11
Exhibit 99.2 CONVENING NOTICE This is the convening notice for the Annual General Meeting of shareholders of Pharvaris N.V. (the "Company") to be held on June 26, 2026 at 4:00 p.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Discussion of Dutch statutory board report for the fiscal year ended December 31, 2025 (discussion item) 3. Adoption of Dutch statutory annual accou…
Read attachment ↗